Constellation Pharmaceuticals (NASDAQ:CNST) Shares Down 5.9%

Shares of Constellation Pharmaceuticals Inc (NASDAQ:CNST) were down 5.9% during trading on Tuesday . The company traded as low as $30.82 and last traded at $32.34, approximately 548,100 shares traded hands during trading. An increase of 278% from the average daily volume of 145,072 shares. The stock had previously closed at $34.38.

A number of equities analysts recently commented on CNST shares. Oppenheimer boosted their target price on shares of Constellation Pharmaceuticals from $18.00 to $40.00 in a research note on Wednesday, November 6th. ValuEngine downgraded shares of Constellation Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 15th. Zacks Investment Research downgraded shares of Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Royal Bank of Canada boosted their target price on shares of Constellation Pharmaceuticals to $42.00 and gave the stock a “positive” rating in a research note on Thursday, November 7th. Finally, BMO Capital Markets boosted their target price on shares of Constellation Pharmaceuticals from $17.00 to $43.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. Constellation Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $36.96.

The company has a debt-to-equity ratio of 0.81, a current ratio of 5.19 and a quick ratio of 5.19. The company has a market cap of $798.18 million, a price-to-earnings ratio of -6.47 and a beta of 5.32. The firm’s 50 day simple moving average is $13.01 and its 200-day simple moving average is $10.35.

Constellation Pharmaceuticals (NASDAQ:CNST) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. On average, analysts forecast that Constellation Pharmaceuticals Inc will post -2.95 EPS for the current year.

In related news, major shareholder Group L. P. Column acquired 1,411,764 shares of the firm’s stock in a transaction on Thursday, October 3rd. The stock was bought at an average price of $8.50 per share, for a total transaction of $11,999,994.00. Also, Director Anthony B. Evnin bought 2,823,529 shares of Constellation Pharmaceuticals stock in a transaction dated Thursday, October 3rd. The stock was acquired at an average cost of $8.50 per share, with a total value of $23,999,996.50. Insiders sold 130,855 shares of company stock valued at $3,775,855 in the last 90 days. 43.70% of the stock is currently owned by insiders.

Several large investors have recently made changes to their positions in the company. Wells Fargo & Company MN raised its holdings in shares of Constellation Pharmaceuticals by 42.1% in the second quarter. Wells Fargo & Company MN now owns 13,937 shares of the company’s stock valued at $171,000 after buying an additional 4,132 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Constellation Pharmaceuticals in the second quarter valued at about $61,000. Northern Trust Corp raised its holdings in shares of Constellation Pharmaceuticals by 12.7% in the second quarter. Northern Trust Corp now owns 146,358 shares of the company’s stock valued at $1,797,000 after buying an additional 16,548 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Constellation Pharmaceuticals in the second quarter valued at about $329,000. Finally, P.A.W. Capital Corp raised its holdings in shares of Constellation Pharmaceuticals by 33.3% in the third quarter. P.A.W. Capital Corp now owns 160,000 shares of the company’s stock valued at $1,034,000 after buying an additional 40,000 shares during the last quarter. 65.85% of the stock is owned by institutional investors and hedge funds.

About Constellation Pharmaceuticals (NASDAQ:CNST)

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.

Featured Article: What is a growth and income fund?

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.